Receptor, ErbB-2

"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.

Descriptor ID	D018719
MeSH Number(s)	D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
Concept/Terms	Receptor, ErbB-2 Receptor, ErbB-2 ErbB-2 Receptor Antigens, CD340 CD340 Antigens Proto-Oncogene Proteins c-erbB-2 Proto Oncogene Proteins c erbB 2 p185(c-neu) c-erbB-2 Protein c erbB 2 Protein erbB-2 Proto-Oncogene Protein Proto-Oncogene Protein, erbB-2 erbB 2 Proto Oncogene Protein erbB-2 Receptor Protein-Tyrosine Kinase erbB 2 Receptor Protein Tyrosine Kinase neu Proto-Oncogene Protein Proto-Oncogene Protein, neu neu Proto Oncogene Protein HER-2 Proto-Oncogene Protein HER 2 Proto Oncogene Protein Proto-Oncogene Protein, HER-2 Proto-Oncogene Protein HER-2 Proto Oncogene Protein HER 2 Receptors, erbB-2 erbB-2 Receptors Neu Receptor Receptor, Neu Metastatic Lymph Node Gene 19 Protein Proto-oncogene Protein Neu Neu, Proto-oncogene Protein Proto-oncogene c-ErbB-2 c-ErbB-2, Proto-oncogene Tyrosine Kinase-type Cell Surface Receptor HER2 Tyrosine Kinase type Cell Surface Receptor HER2 p185erbB2 Protein CD340 Antigen Oncogene Protein HER-2 Oncogene Protein HER 2 Proto-Oncogene Protein p185(neu)

Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
ErbB Receptors [D08.811.913.696.620.682.725.400.009]
Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
ErbB Receptors [D12.776.543.750.630.009]
Receptor, ErbB-2 [D12.776.543.750.630.009.400]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
ErbB Receptors [D12.776.543.750.750.400.074]
Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Receptor, ErbB-2 [D12.776.624.664.700.642]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Histocompatibility Antigens [D23.050.301.500]
Minor Histocompatibility Antigens [D23.050.301.500.600]
Receptor, ErbB-2 [D23.050.301.500.600.700]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
Minor Histocompatibility Antigens [D23.050.705.552.600]
Receptor, ErbB-2 [D23.050.705.552.600.550]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Receptor, ErbB-2 [D23.101.140.642]

Below are MeSH descriptors whose meaning is related to "Receptor, ErbB-2".

Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.

Bar chart showing 42 publications over 20 distinct years, with a maximum of 4 publications in 2003 and 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
2001	1	0	1
2002	0	1	1
2003	3	1	4
2004	3	1	4
2005	0	1	1
2006	0	2	2
2007	0	1	1
2008	0	2	2
2009	1	1	2
2010	1	1	2
2011	0	3	3
2012	1	0	1
2013	1	0	1
2015	2	1	3
2016	1	2	3
2017	1	2	3
2018	2	0	2
2019	1	2	3
2020	1	1	2

Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.

Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, Kuhn EP, Kolarova T, Hage C, Ganesh K, Panayiotou R, Foster R, Rueda BR, Aktipis A, Spellman P, Ince TA, Xiu J, Oberley M, Gatalica Z, Navin N, Mills GB, Bronson RT, Brugge JS. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020 11 16; 11(1):5799.

View in: PubMed
Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih SW, Kadamberi IP, Gopinadhan Nair GK, Lu Y, Ramchandran R, Uyar DS, Rader JS, Ram PT, Mills GB, Pradeep S, Chaluvally-Raghavan P. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Cancer Res. 2020 12 15; 80(24):5554-5568.

View in: PubMed
Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019 12; 8(17):7322-7329.

View in: PubMed
Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.

View in: PubMed
Garcia-Flores AE, Sollome JJ, Thavathiru E, Bower JL, Vaillancourt RR. HER2/HER3 regulates lactate secretion and expression of lactate receptor mRNA through the MAP3K4 associated protein GIT1. Sci Rep. 2019 07 25; 9(1):10823.

View in: PubMed
Ma Z, Kim YM, Howard EW, Feng X, Kosanke SD, Yang S, Jiang Y, Parris AB, Cao X, Li S, Yang X. DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability. Oncol Rep. 2018 Sep; 40(3):1632-1640.

View in: PubMed
Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? Am J Clin Pathol. 2018 May 31; 150(1):34-42.

View in: PubMed
Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017 08; 30(8):1078-1085.

View in: PubMed
Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. Bosn J Basic Med Sci. 2017 Feb 21; 17(1):9-11.

View in: PubMed
Ma Z, Parris AB, Xiao Z, Howard EW, Kosanke SD, Feng X, Yang X. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. J Exp Clin Cancer Res. 2017 01 06; 36(1):6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals